Xiaohou Wu

First Affiliated Hospital of Chongqing Medical University — China

Medicine · Health Sciences

27h-index2.1kcitations144works2.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(16), Cancer, Hypoxia, and Metabolism(16), Cancer-related Molecular Pathways(12), Extracellular vesicles in disease(12), Bladder and Urothelial Cancer Treatments(11)

Publications144 total

Hypoxia-Induced VGF Promotes Cell Migration and Invasion in Prostate Cancer via the PI3K/Akt Axis
Frontiers in Bioscience-Landmark·2025· 2 citedOpen Access
Analysis of factors associated with delayed diagnosis and treatment of testicular torsion in 1005 cases from Chongqing city, China: a cross-sectional study
Scientific Reports·2023· 10 citedOpen Access
A new treatment of concealed penis: symmetrical pterygoid flap surgery
International braz j urol·2023· 8 citedOpen Access
Predictive model for persistent hypertension after surgical intervention of primary aldosteronism
Scientific Reports·2023· 5 citedOpen Access
Relationship between rumination and post-traumatic growth in mobile cabin hospital nurses: The mediating role of psychological resilience
Preventive Medicine Reports·2023· 15 citedOpen Access
Initial Experience of Simultaneous Combined use of Percutaneous Nephrolithotomy and Flexible Ureteroscopy in Complex Renal Calculi: A Novel Surgical Technique of ‘Through-Through’ Approach
Surgical Innovation·2023· 2 cited
Primary large cell carcinoma of ureter ： a case report and review of the literature
2023Open Access
Primary large cell carcinoma of ureter ： a case report and review of the literature
2022Open Access
[Corrigendum] PLCε knockdown enhances the radiosensitivity of castration‑resistant prostate cancer via the AR/PARP1/DNA‑PKcs axis
Oncology Reports·2022Open Access
[Corrigendum] Combination of phospholipase Cε knockdown with GANT61 sensitizes castration‑resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway
Oncology Reports·2022Open Access
Predictive model for persistent hypertension after surgical intervention of primary aldosteronism
Research Square (Research Square)·2022Open Access
[Corrigendum] HepaCAM inhibits cell proliferation and invasion in prostate cancer by suppressing nuclear translocation of the androgen receptor via its cytoplasmic domain
Molecular Medicine Reports·2022Open Access
Lycopene enhances the sensitivity of castration-resistant prostate cancer to enzalutamide through the AKT/EZH2/ androgen receptor signaling pathway
Biochemical and Biophysical Research Communications·2022· 20 cited
Long non-coding RNA lncHUPC1 induced by FOXA1 promotes tumor progression by inhibiting apoptosis via miR-133b/SDCCAG3 in prostate cancer.
PubMed·2022· 9 citedOpen Access
Identification of the metabolic signatures of prostate cancer by mass spectrometry‐based plasma and urine metabolomics analysis
The Prostate·2021· 22 cited
Panobinostat reverses HepaCAM gene expression and suppresses proliferation by increasing histone acetylation in prostate cancer
Gene·2021· 10 cited
MicroRNA-199b-3p suppresses malignant proliferation by targeting Phospholipase Cε and correlated with poor prognosis in prostate cancer
Biochemical and Biophysical Research Communications·2021· 20 cited
Systematic Evaluation for the Influences of the SOX17/Notch Receptor Family Members on Reversing Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells
Frontiers in Oncology·2021· 13 citedOpen Access
Ionizing Radiation Combined with PARP1 Inhibitor Reduces Radioresistance in Prostate Cancer with RB1/TP53 Loss
Cancer Investigation·2021· 9 citedOpen Access
The targeted inhibition of prostate cancer by iron-based nanoparticles based on bioinformatics
Journal of Biomaterials Applications·2020· 7 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Chunli Luo(42), Zhen Quan(12), Yanru Fan(9), Yao Zhang(8), Yunfeng He(8), Xuedong Song(6), Liping Ou(6), Yanni Hao(4), Jiaxin Fan(4), Limei Duan(4), Mengjuan Yuan(4), Lingfang Niu(4), Xiaorong Wang(4), Xue Yang(4), Hongfei Du(4), Jiamo Zhang(3), Jinxiao Yang(3), Chaowen Yu(3), Yan Zhao(3), Bing Tan(3)